Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate

Leukemia Research

Volumn 31, Issue 4, 2007, Pages 563-567

  Pompetti, Franca ^a   Spadano, Antonio ^a   Sau, Antonella ^a   Mennucci, Antonio ^a   Russo, Rosa ^a   Catinella, Virginia ^a   Franchi, Paolo Guanciali ^a   Calabrese, Giuseppe ^a   Palka, Giandomenico ^a   Fioritoni, Giuseppe ^a   Iacone, Antonio ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

AML; BCR ABL; Imatinib

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; ETHAMBUTOL; ETOPOSIDE; IMATINIB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER GENETICS; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERPYREXIA; LEUKEMIA REMISSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION;

EID: 33846796420     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.05.021     Document Type: Article

References (20)

1. Cuneo A., Ferrant A., Michaux J.L., et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 81 (1996) 423-427
2. Paietta E., Racevskis J., Bennett J.M., et al. Biologic heterogeneity in Philadelphia chromosome-positive acute leukemia with myeloid morphology: the Easten Cooperative Group experience. Leukemia 12 (1998) 1881-1885
3. Hirsch-Ginsberg C., Childs C., Chang K.S., Beran M., et al. Phenotypic and molecular heterogeneity in Philadelphia chromosome-positive acute leukemia. Blood 71 1 (1988) 186-195
4. Saglio G., Guerrasio A., Tassinari A., Ponzetto C., Zaccaria A., et al. Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies. Blood 72 4 (1988) 1203-1208
5. Haskovec C., Ponzetto C., Polak J., Maritano D., et al. p230 BCR/ABL protein may be associated with an acute leukemia phenotype. Br J Haematol 103 (1998) 1104-1108
6. Balatzenko G., Guenova M., Zechev J., and Toshkov S. Acute megakaryoblastic leukemia with extreme thrombocytosis and p190 (BCR/ABL) rearrangement. Ann Hematol 83 6 (2004) 381-385
7. Cuneo A., Balboni M., Piva N., Carli M.G., Tomasi P., et al. Lineage switch and multilineage involvement in two cases of Ph chromosome-positive acute leukemia: evidence for a stem cell disease. Haematologica 79 (1994) 76-82
8. Kolb E.A., Pan Q., Ladanyi M., and Steinhertz P.G. Imatinib Mesylate in Ph chromosome-positive leukemia of childhood. Cancer 98 12 (2003) 2643-2650
9. Yamaguchi M., and Konishi I. Successful treatment with Imatinib Mesylate for Ph chromosome-positive refractory acute myeloid leukemia. Rinsho Ketsueki 44 4 (2003) 254-256 (in Japanese, with English abstract)
10. Jentsch-Ullrich K., Pelz A.-F., Braun H., et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and Imatinib. Haematologica 89 5 (2004) ecr15
11. Viniou N.A., Vassilakopoulos T.P., Giakoumi X., Mantzouranis M., and Pangalia G.A. Ida-FLAG plus Imatinib Mesylate-induced molecular remission in a patient with chemoresistant Ph1(+) acute myeloid leukemia. Eur J Haematol 72 (2004) 58-60
12. Ito K., Tominaga K., Suzuti T., Jinnai I., and Bessho M. Successful treatment with Imatinib Mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol 81 3 (2005) 242-245
13. Olopade O.I., Thangavelu M., Larson R.A., Mick R., et al. Clinical morphologic and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood 80 11 (1992) 2873-2882
14. Yamamoto K., Nakamura Y., Arai H., Saito K., and Furusawa S. Triple Philadelphia chromosomes with major-bcr rearrangement in hypotriploid erythroleukemia. Eur J Haematol 65 3 (2000) 182-187
15. Sandberg AA. The chromosomes in human cancer and leukemia. 2nd ed. (1990), Elsevier, New York p. 203-215
16. O'Brien S., Tefferi A., and Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) (2004) 146-162 (review)
17. Higashi T., Tsukada J., Kato C., et al. Imatinib Mesylate-sensitive blast crisis immediately after discontinuation of Imatinib Mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 76 (2004) 275-278
18. Mauro M.J., Druker B.J., and Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued Imatinib therapy after achieving a molecular remission. Leuk Res 28 Suppl 1 (2004) S71-S73
19. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent Philadelphia positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
20. Bhatia R., Holtz M., Niu N., et al. Persistence of malignant hemopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following Imatinib Mesylate treatment. Blood 101 (2003) 4701-4707